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BACKGROUND: Precision medicine in breast cancer demands markers sensitive to early treatment response. Aerobic glycolysis
(AG) upregulates lactate dehydrogenase A (LDH-A) with elevated lactate production; however, existing approaches for lactate
quantification are either invasive or impractical clinically.
METHODS: Thirty female patients (age 39–78 years, 15 grade II and 15 grade III) with invasive ductal carcinoma were enrolled.
Lactate concentration was quantified from freshly excised whole tumours with double quantum filtered (DQF) magnetic resonance
spectroscopy (MRS), and Nottingham Prognostic Index (NPI), LDH-A and proliferative marker Ki-67 were assessed histologically.
RESULTS: There was a significantly higher lactate concentration (t= 2.2224, p= 0.0349) in grade III (7.7 ± 2.9 mM) than in grade II
(5.5 ± 2.4 mM). Lactate concentration was correlated with NPI (ρ= 0.3618, p= 0.0495), but not with Ki-67 (ρ= 0.3041, p= 0.1023) or
tumour size (r= 0.1716, p= 0.3645). Lactate concentration was negatively correlated with LDH-A (ρ=−0.3734, p= 0.0421).
CONCLUSION: Our results showed that lactate concentration in whole breast tumour from DQF MRS is sensitive to tumour grades
and patient prognosis.
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BACKGROUND
The 10-year survival rate of breast cancer has improved
substantially from 40.1 to 78.4% in the last 40 years,1 primarily
resulting from advancement in chemotherapy2 and targeted
endocrine modulation.3 Non-responding patients not only are
exposed to side effects and possible life threatening complica-
tions,4 but also may experience disease progression during
treatment and delayed surgery,5 demanding an early response
marker beyond crude tumour size. Aerobic glycolysis (AG),
a central feature of tumour metabolism, fuels rapid growth
with elevated glucose consumption and subsequent lactate
production.6 Malignant transformation is underscored by genetic
mutation, activating hypoxia inducible factor 1 (HIF-1) and
subsequent upregulation of lactate dehydrogenase A (LDH-A),
leading to increased conversion of pyruvate to lactate and the
efflux of lactate through monocarboxylate transporter 4 (MCT4).7
The accumulation of lactate generates an acidic environment
suppressing normal immunological functions while providing
fuel to tumour cells, resulting in accelerated local invasion.8 The
inhibition of lactate production induces tumour regression in
cancer xenografts, underpinning the role of lactate concentration
as a response marker.9
Biochemical approaches, although capable of lactate concen-
tration quantification, are performed on excised tissue or biopsy
samples with limited spatial extent. 18F-Fluorodeoxyglucose (FDG)
positron emission tomography (PET) sensitive to glucose uptake,
suffers from the dependency on glucose delivery and exposure
of patients to ionising radiation.10 Hyperpolarised 13C-pyruvate
magnetic resonance spectroscopic imaging maps the conversion
of pyruvate to lactate, but suffers from the high cost of labelled
pyruvate and specialist equipment.11 Conventional 1H magnetic
resonance spectroscopy (MRS) allows lactate quantification in
neuro-oncology,12 but suffers from overwhelming contamination
signal from lipid in breast. Double quantum filtered (DQF) MRS, a
method recently available for clinical research,13 allows lactate
quantification in high lipid tissue such as breast using standard
hardware, but was so far only examined in proof of concept case
studies.14
We therefore hypothesise that lactate concentration derived
from DQF MRS is sensitive to tumour grades and is associated with
prognosis.
METHODS
To probe the hypothesis, we conducted a two-group cross
sectional study examining the lactate concentration of whole
tumour freshly excised from patients, with further comparison
against histopathological findings (Fig. 1).
Study approval
The study was approved by the North West–Greater Manchester
East Research Ethics Committee (REC Reference: 16/NW/0032), and
signed written informed consent was obtained from the patients
prior to inclusion in the study.
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Patients
Thirty female patients (age 39–78 years, 15 grade II and 15 grade
III) with invasive ductal carcinoma were enrolled in the study. Only
patients undergoing wide local excision or mastectomy, and with
a tumour size larger than 1 cm in diameter on ultrasound were
eligible. Patients with previous breast malignancies or who had
undergone prior neoadjuvant chemotherapy or neoadjuvant
hormonal therapy were not eligible. In total, 50 patients
consented to be included in the study from 53 consecutive
patients in the Breast Unit at Aberdeen Royal Infirmary. From
these 50 resected tumour specimens, 39 were scanned, with the
remainder excluded because of either theatre delays or MRI
scanner unavailability. Following histopathological examination of
the excised tumour, alterations in tumour subtype or grade from
biopsy that classified the tumour differently from grade II/III
invasive ductal in type were excluded. In total, nine tumour
specimens, including two lobular phenotype, five mixed pheno-
type and two grade I, were excluded.
Power calculation was based on Cohen’s d,15 using the
reported difference in lactate concentration of 2 mM between
aggressive and non-aggressive tumours in xenografted mice
models,16 and standard deviation (SD) of 3 mM determined from
repeated phantom experiment. Therefore, to show a significant
mean difference between groups at the 5% level with 80%
power using an independent sample design would require
15 subjects per group.17
Magnetic resonance
After wide local excision or mastectomy, the fresh tissue
(without formalin treatment) was immediately transported to
the Aberdeen Biomedical Imaging Centre (transportation time
less than 5 min, Fig. 1). The ex vivo specimen was scanned in air
and positioned in the isocentre of the scanner. The data were
acquired on a 3 T whole-body clinical MRI scanner (Achieva TX,
software version R5.1.7, Philips Healthcare, Best, Netherlands)
using a body coil for uniform transmission and a 32-channel
receiver head coil for high sensitivity detection. The DQF
sequence was implemented locally using Philips Pulse Program-
ming Environment (PPE). The T1-weighted anatomical images
were acquired using standard 3D sequence with an isotropic
voxel size of 1 mm, matrix size of 220 × 220, repetition time (TR)
of 5.2 ms, echo time (TE) of 2.7 ms, imaging volume encom-
passing the specimen. Subsequently, the lactate spectrum was
acquired from a single voxel snug-fit to the tumour using single
voxel DQF PRESS sequence,13 with TR/TE of 1.25 s/144 ms,
spectral editing frequency at 4.1 ppm and 512 averages.
A reference spectrum was acquired from the same voxel using
single voxel PRESS sequence with TR/TE of 1.25 s/144 ms,
16 averages. The total acquisition time for lactate spectrum
was 11 min.
All spectra were processed following standard procedures
and quantified using AMARES algorithm18 in the jMRUI software
(v3.0, TRANSACT, Leuven, Belgium).19 Water and lactate ampli-
tudes were quantified from reference and lactate spectra,
respectively, using corresponding prior knowledge databases.20
The lactate concentration in the tumour was then computed from
water and lactate amplitudes, literature breast tissue biochemical
composition and relaxation properties on the 3 T scanner.21 The
quantification of lactate concentration was conducted following
written procedure and blinded from group allocation. Full details
of quantification and spectra from breast tumour specimens are
provided in Supplementary Information.
Approached for eligibility (n = 53)
Declined to participate (n = 3)
Consented for study (n = 50)
Surgery
Magnetic resonance spectroscopy (MRS) (n = 39)
Lactate concentration
Pathology
Tumour grade, size, histological type,
LDH-A, LDH-B, Ki-67, NPI
Logistic challenge (n = 11)
Grade II IDC (n = 15) Grade III IDC (n = 15)
Lobular (2), mixed phenotype (5)
or grade I (2) (n = 9)
Fig. 1 Study design. The study adopted a two-group cross sectional arrangement as shown in this flow chart. Among 53 consecutive patients
identified and approached, 50 patients were consented and received wide local excision or mastectomy. After surgery, the freshly excised
tumours were scanned on a clinical 3 T MRI scanner to derive lactate concentration within the whole tumour using double quantum filtered
(DQF) magnetic resonance spectroscopy (MRS). Subsequently, histopathological analysis provided tumour grade, size, histological type,
lactate dehydrogenase A and B (LDH-A and LDH-B), Ki-67 expression and Nottingham Prognostic Index (NPI). Thirty patients with invasive
ductal carcinoma (IDC) (15 grade II and 15 grade III) were eventually entered into the study and used for all statistical analysis.
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Histopathological analysis
Upon the completion of scanning, the specimen was immedi-
ately transported to the Pathology Department at Aberdeen
Royal Infirmary (transportation time less than five minutes,
Fig. 1) for formalin fixation. Routine clinical histopathological
examination was undertaken on the specimen to define the
tumour characteristics (including size and grade) along with
the nodal status for Nottingham Prognostic Index (NPI).22
Subsequently, immunostaining was performed in a single batch
for Ki-67,23 LDH-A24 and LDH-B25 including appropriate positive
controls. The immunostains were assessed semi-quantitatively
by two pathologists independently (EH and IM), blinded from
group allocation.
Statistical analysis
All statistical analysis was performed in the SPSS software (Release
23.0, SPSS Inc., Chicago, IL, USA). Normality was determined on all
the collected data using the Shapiro-Wilk test. Two-sample t-tests
were performed on normally distributed data to assess difference
between tumours with grade II and grade III histology, and Mann-
Whitney U tests for non-normally distributed data. Fisher’s exact
tests were applied to study the association between grades and
other tumour pathological features. Pearson’s correlation test was
performed between lactate concentration and tumour size, with
Spearman’s rank correlation tests for lactate concentration against
NPI, Ki-67 and LDH-A. A p-value < 0.05 was considered statistically
significant.
RESULTS
The patient characteristics are shown in Table 1. All patient
demographics, apart from NPI, were normally distributed. There
were no significant differences in age, body mass index and tumour
size between groups. Lactate was measurable in all spectra, defined
as Cramér-Rao lower bound (CRLB) of the fit below 30%.
There was a significantly higher (t= 2.2224, p= 0.0349) lactate
concentration in grade III (7.7 ± 2.9 mM) than in grade II (5.5 ±
2.4 mM) (Table 2, Fig. 2a). NPI was significantly higher (z= 3.819, p
= 0.0001) in grade III (median: 4.50; interquartile range (IQR):
4.44–5.02) than in grade II (median: 3.46; IQR: 3.46–4.29) (Table 1,
Fig. 2b). There was a significantly higher (z= 3.712, p= 0.0002)
Ki-67 expression in grade III (median: 22.9%, IQR: 16.7–40.2%) than
in grade II (median: 9.7 %, IQR: 6.3–16.4%) (Table 2, Fig. 2c). There
was a significantly higher (z= 2.743, p= 0.0061) LDH-A expression
in grade II (median: 300, IQR: 250–300) than in grade III (median:
100, IQR: 80–250) (Table 2, Fig. 2d). There was a significantly higher
(z= 2.821, p= 0.0048) LDH-B expression in grade III (median: 40,
IQR: 0–120) than in grade II (median: 0, IQF: 0–10) (Table 2).
There was a significant correlation between lactate concentra-
tion and NPI (ρ= 0.3618, p= 0.0495, Table 2, Fig. 3a). There were
no significant correlations between lactate concentration against
Ki-67 expression (ρ= 0.3041, p= 0.1023, Table 2, Fig. 3b) or
tumour size (r= 0.1716, p= 0.3645, Fig. 3c). There was a
significant negative correlation between lactate concentration
and LDH-A (ρ=−0.3734, p= 0.0421, Table 2, Fig. 3d).
DISCUSSION
In this work, we found lactate concentration was significantly
higher in grade III breast tumours compared to grade II. Increased
lactate concentration was associated with worse NPI, not
associated with tumour proliferative activity or tumour size,
and negatively associated with LDH-A expression. Hence, lactate
concentration derived from DQF MRS is a marker sensitive to
tumour grades, with an association to prognosis.
Lactate concentration, observed in this study, is in agreement
with findings in breast cancer cell culture,26 xenografted animal
tumour models,16 ex vivo human brain tumours27 and brain
tumours in patients.12 Since accumulated lactate alters the
cellular physical appearance through the inflammatory
activities and deregulation of immune function,8 the sensitivity
to tumour grade is through the sub-scores associated with
cellular appearance of tubule formation, nuclear pleomor-
phism and mitoses. Lactate concentration quantified over the
entire tumour addresses the drawbacks in biopsy methods of
intratumoural heterogeneity and partial sampling error. Lactate
concentration is a quantitative objective measure compared to
immunostaining methods and FDG-PET, reducing the demand
on manpower and ambiguity. Hence, lactate concentration from
DQF MRS is a non-invasive marker sensitive to tumour grade,
with significant advantages over current methods for
quantifying AG.
The correlation between lactate concentration and NPI indicates
the prognostic value of lactate concentration in breast cancer, in
Table 1. Patient demography.
Characteristic All (n= 30) Grade II (n= 15) Grade III (n= 15) p-value
Age 61.1 ± 11.5 61.0 ± 12.0 61.2 ± 11.3 0.9628
Body mass index (BMI) 30.4 ± 6.4 30.4 ± 6.6 30.3 ± 6.6 0.9771
Tumour size (cm) 2.5 ± 0.8 2.4 ± 0.9 2.5 ± 0.7 0.7650
Tumour volume (cm3)a 20.0 ± 21.3 20.3 ± 19.2 19.6 ± 23.9 0.9335
Nottingham prognostic index (NPI) 4.41 (3.62–4.56) 3.62 (3.46–4.29) 4.50 (4.44–5.02) 0.0001*
Tumour type
pTNM Stage
I 5 3 2 1.000
II 25 12 13
Lymphovascular invasion (LVI) 17 9 8 1.000
Lymph node involvement 8 4 4 1.000
Oestrogen receptor (ER+) 22 13 9 0.215
Human epidermal growth factor receptor 2 (HER2+) 6 2 4 0.651
Triple-negative breast cancer (TNBC) 7 1 6 0.080
Patient demography and clinical histopathological findings of excised breast tumours are shown for each group and the entire cohort. Quantitative data are
expressed as mean and standard deviation (apart from Nottingham Prognostic Index where median and interquartile range are shown), while qualitative data
expressed as number of positive cases.
*Significant findings (p < 0.05) are marked.
aTumour volume extracted from T2-weighted MRI.
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line with elevated release of lactate in highly malignant breast
cancer cells.26 Lactate supports advancing epithelial cancer cells as
energy source,6 while macrophage function is severely compro-
mised at high lactate concentration (>15mM) with diminished
production of natural killer cells and apoptosis of T cells.8 Lactate
concentration does not show significant correlation with crude
tumour size or Ki-67, underscoring lactate concentration as a
specific marker to AG. Proliferative activity marker Ki-67 reveals
the rate of division of cellular nuclear materials28 (that is possibly
discordant with the mitotic index29), while lactate enhances the
survival advantage of tumour cells reflecting invasion capability.6
The negative correlation against LDH-A was likely the result of
feedback inhibition30 and depletion of pyruvate and nicotinamide
adenine dinucleotide hydrogen (NADH)31 in higher grade tumour.
The observed higher expression of LDH-A has been previously
found in less aggressive 67NR breast cancer cells under hypoxia in
preclinical model16 and more differentiated tumours in patients
with gastric cancer,32 while observed higher LDH-B in higher
grade is in agreement with previous studies in breast cancer.33
However, carbonic anhydrase IX (CA9), a strong prognostic
marker, has been recently shown to induce an acidic tumour
extracellular pH in vivo,34 decoupling lactate production regulated
by LDH and lactate concentration. Hence, lactate concentration is
a sensitive prognostic marker, specific to the invasion capability
resulted from an acidic extracellular environment.
The lactate concentration obtained from single voxel
approach is an average over the whole tumour, and does not
inform the spatial distribution of lactate within tumour, limiting
the accuracy in the cases with large disparity between tumour
core and rim.26 Although triple-negative breast cancer is
postulated to be more aggressive, there is no significant
difference in lactate concentration between triple-negative (6
cases, mean: 8.4 mM) and non-triple-negative (nine cases,
mean: 7.2 mM) in our grade III cohort, indicating no proven
relation to this potential confounding factor. The deterioration
of tissue after excision may affect the accuracy of lactate
concentration quantification; however, the median time gap
from excision to the middle of the DQF MRS scan was 25 min,
significantly below the time frame for observing change in
lactate concentration in postmortem tissues (3 h).35 The freshly
excised tumour allows the use of a high sensitivity receiver
head coil for improved measurement accuracy, while eliminat-
ing biological noise. Restriction of tumours to grade II and III
with a size larger than 1 cm (24 specimens>2 cm) is to represent
patient population likely receiving neoadjuvant therapy. The
restriction of phenotype to invasive ductal carcinoma, the most
common breast cancer, eliminates phenotype as a confounding
factor, allowing adequate statistical power in a small patient
cohort. The sample size is small; however, careful power
calculation was conducted to assess the appropriate sample
size16 before the evaluation of the lactate concentration from
ex vivo tumours.
The current acquisition of lactate spectrum was long (11 min)
and only suitable for lactate concentrations higher than 1.5 mM,
demanding future development work to improve the sensitivity.
Lactate was measurable in all spectra, and quantification was
limited to lactate spectra with CRLB below 30%. The overlap of the
distribution in lactate concentration between groups limits the
prognostic value of lactate concentration obtained using current
methodology in breast cancer. MRS is well known to have high
specificity but low sensitivity. Future technological improvement
including digital hardware and adaptive signal processing for
phased array coils36 should be incorporated in further develop-
ment to improve prognostic value. Future longitudinal studies on
patients undergoing neoadjuvant chemotherapy will confirm the
prognostic and treatment monitoring value of lactate concentra-
tion, and multicentre study with larger cohort size covering a
complete range of phenotypes is essential for clinical adoption.T
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Lactate concentration from DQF MRS is a non-invasive marker
sensitive to breast tumour grade and is associated with NPI as
demonstrated in a cross sectional study. Lactate concentration
provides a valuable clinical research tool for potential identifica-
tion of treatment targets and application to improve image
guided neoadjuvant chemotherapy.
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